ATEA PHARMACEUTICALS INC (AVIR) Stock Price, Forecast & Analysis
USA - NASDAQ:AVIR - US04683R1068 - Common Stock
AVIR Key Statistics, Chart & Performance
The current stock price of AVIR is 3.38 USD. In the past month the price increased by 7.07%. In the past year, price increased by 3.42%.
AVIR Latest News, Press Relases and Analysis
AVIR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.74 | 931.21B | ||
| JNJ | JOHNSON & JOHNSON | 18.34 | 458.55B | ||
| MRK | MERCK & CO. INC. | 10.2 | 224.45B | ||
| PFE | PFIZER INC | 7.75 | 141.09B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.34 | 97.99B | ||
| ZTS | ZOETIS INC | 19.13 | 53.74B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.52 | 22.83B | ||
| VTRS | VIATRIS INC | 4.57 | 12.42B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.83 | 11.37B | ||
| CORT | CORCEPT THERAPEUTICS INC | 88.99 | 8.25B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.04B | ||
| LGND | LIGAND PHARMACEUTICALS | 29.04 | 4.15B |
Related stock screener links
About AVIR
Company Profile
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Company Info
ATEA PHARMACEUTICALS INC
225 Franklin Street, Suite 2100
Boston MASSACHUSETTS 02110 US
CEO: Jean-Pierre Sommadossi
Employees: 56
Phone: 18572048109
ATEA PHARMACEUTICALS INC / AVIR FAQ
What does ATEA PHARMACEUTICALS INC do?
Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2020-10-30. The firm is focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. The firm has built a proprietary nucleos(t)ide prodrug platform to develop product candidates to treat single-stranded ribonucleic acid (ssRNA) viruses, which are a prevalent cause of serious viral diseases. The Company’s lead program and focus is on the development of the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an investigational, potent, small-molecule inhibitor of hepatitis C virus (HCV) non-structural protein 5A (NS5A), an essential protein for HCV replication. Bemnifosbuvir is an investigational, orally administered guanosine nucleotide double prodrug which targets the HCV non-structural protein 5B (NS5B) RNA-dependent RNA polymerase and inhibits HCV replication.
Can you provide the latest stock price for ATEA PHARMACEUTICALS INC?
The current stock price of AVIR is 3.38 USD. The price increased by 1.5% in the last trading session.
What is the dividend status of ATEA PHARMACEUTICALS INC?
AVIR does not pay a dividend.
What is the ChartMill rating of ATEA PHARMACEUTICALS INC stock?
AVIR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the PE ratio for AVIR stock?
ATEA PHARMACEUTICALS INC (AVIR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
Would investing in ATEA PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AVIR.
AVIR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to AVIR. When comparing the yearly performance of all stocks, AVIR is a bad performer in the overall market: 63% of all stocks are doing better.
AVIR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to AVIR. No worries on liquidiy or solvency for AVIR as it has an excellent financial health rating, but there are worries on the profitability.
AVIR Financial Highlights
Over the last trailing twelve months AVIR reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 23.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.76% | ||
| ROE | -37.35% | ||
| Debt/Equity | 0 |
AVIR Forecast & Estimates
8 analysts have analysed AVIR and the average price target is 6.12 USD. This implies a price increase of 81.07% is expected in the next year compared to the current price of 3.38.